Despite considerable clinical impact of blocking checkpoints such as PD1 and LAG3, the mechanisms remain poorly understood. One remaining gap is how PD1 and LAG3 regulate formation of TEX precursors early in chronic infection and mature TEX subsets later. Answering this question will identify molecular mechanisms that link PD1 and LAG3 to preventing or reversing exhaustion and new therapeutic opportunities. We hypothesize that individual and combined signals from PD1 and LAG3 engage temporally distinct, therapeutically relevant mechanisms to regulate T cell exhaustion that will be discovered by dissecting the synergy between these pathways at different stages of T cell exhaustion. This project will address this hypothesis by testing:
Aim 1 : How do signals from PD1 or LAG3 or both promote formation of TEX precursors? Here, we will reveal how PD1 and/or LAG3 are involved in initial molecular and cellular establishment of early TEX formation and provide opportunities for preventing development of exhaustion. We hypothesize that PD1 and/or LAG3 are necessary to initiate and temporally reinforce development of TEX during chronic viral infection through mechanisms that involve TCF1, NFAT, and/or TOX. We will use constitutive or inducible CD8 T cell-intrinsic PD1 and/or LAG3 deficiency together with antibody (Ab) blockade and novel exhaustion tracking mice (i.e.Lag3CreERT2.Rosa26LSL.tdTomato or ToxCreERT2.Rosa26LSL.tdTomato) from Core B. Thus, Aim 1 will deliver detailed maps of how PD1 and LAG3 separately and together regulate initial formation of TEX.
Aim 2 : What are the molecular and epigenetic events caused by temporally induced loss of PD1 or LAG3 in mature TEX subsets? Despite the clinical relevance of checkpoint blockade, the underlying biology of TEX reinvigoration remains poorly understood, particularly surrounding early molecular events associated with reinvigoration in vivo and its impact on different TEX subsets. We hypothesize that early molecular events following removal of PD1 and/or LAG3 are distinct for different TEX subsets, imparting novel functional, transcriptional, and/or differentiation changes that will enable us to identify new molecular targets to reverse or prevent exhaustion. Here, we will interrogate bulk and single-cell transcriptional as well as epigenetic changes in total TEX and TEX subsets over a high-resolution time-course following removal of PD1 and/or LAG3. Discoveries will be further dissected using in vivo CRISPR/Cas9 screening and RV approaches (Core C). These data will provide important insights for applying PD1 and/or LAG3 blockade in humans. PPG Interactions: Because the core program of exhaustion is conserved in chronic infections, tumors, and autoimmunity, Project 3 will connect extensively with Projects 1 and 2 for experimental models and mechanistic insights from autoimmunity or tumors. We will also coordinate with Core A to exchange data and interact, Core B to obtain mice, Core C for RV approaches and bioinformatics, and Core D for immunohistology.

Public Health Relevance

Chronic infections with viruses such as HIV, HCV and HBV affect half a billion people and are significant causes of morbidity and mortality. T cell dysfunction or ?exhaustion? is a major immunological defect during these infections and can be modeled with LCMV infection in mice. The studies proposed will define the role of the inhibitory receptors PD1 and LAG3 in CD8+ T cell exhaustion and provide new insights into how to reverse and avoid T cell exhaustion and improve immunity during these and other chronic infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI108545-06
Application #
10023670
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2015-05-15
Project End
2025-07-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15260
Stelekati, Erietta; Chen, Zeyu; Manne, Sasikanth et al. (2018) Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. Cell Rep 23:2142-2156
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Overacre-Delgoffe, Abigail E; Vignali, Dario A A (2018) Treg Fragility: A Prerequisite for Effective Antitumor Immunity? Cancer Immunol Res 6:882-887
Ratay, Michelle L; Glowacki, Andrew J; Balmert, Stephen C et al. (2017) Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease. J Control Release 258:208-217
Huang, Alexander C; Postow, Michael A; Orlowski, Robert J et al. (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60-65
Hope, Jennifer L; Stairiker, Christopher J; Spantidea, Panagiota I et al. (2017) The Transcription Factor T-Bet Is Regulated by MicroRNA-155 in Murine Anti-Viral CD8+ T Cells via SHIP-1. Front Immunol 8:1696
Andrews, Lawrence P; Marciscano, Ariel E; Drake, Charles G et al. (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276:80-96
Chen, Zeyu; Stelekati, Erietta; Kurachi, Makoto et al. (2017) miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb. Cell Rep 20:2584-2597
Zhang, Qianxia; Chikina, Maria; Szymczak-Workman, Andrea L et al. (2017) LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci Immunol 2:
Kurachi, Makoto; Kurachi, Junko; Chen, Zeyu et al. (2017) Optimized retroviral transduction of mouse T cells for in vivo assessment of gene function. Nat Protoc 12:1980-1998

Showing the most recent 10 out of 21 publications